Livelsberger Financial Advisory Takes $26,000 Position in Becton, Dickinson and Company (NYSE:BDX)

Livelsberger Financial Advisory acquired a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 109 shares of the medical instruments supplier’s stock, valued at approximately $26,000.

A number of other hedge funds have also recently modified their holdings of BDX. Sound Income Strategies LLC boosted its holdings in Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 44 shares during the period. Opal Wealth Advisors LLC bought a new position in Becton, Dickinson and Company in the 2nd quarter worth $45,000. Abound Wealth Management boosted its holdings in Becton, Dickinson and Company by 96.0% in the 2nd quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock worth $46,000 after buying an additional 96 shares during the period. Chilton Capital Management LLC boosted its holdings in Becton, Dickinson and Company by 1,233.3% in the 2nd quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock worth $47,000 after buying an additional 185 shares during the period. Finally, Tributary Capital Management LLC bought a new position in Becton, Dickinson and Company in the 1st quarter worth $49,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 1.3 %

Becton, Dickinson and Company stock traded down $3.29 during midday trading on Monday, reaching $240.46. The stock had a trading volume of 249,437 shares, compared to its average volume of 1,388,632. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $262.23. The firm has a market cap of $69.49 billion, a price-to-earnings ratio of 53.69, a price-to-earnings-growth ratio of 1.79 and a beta of 0.42. The company has a fifty day moving average of $237.01 and a 200 day moving average of $235.18.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The company had revenue of $4.99 billion for the quarter, compared to analyst estimates of $5.08 billion. During the same period in the prior year, the company posted $2.96 EPS. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. On average, analysts anticipate that Becton, Dickinson and Company will post 13.11 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 30th. Investors of record on Monday, September 9th were given a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a yield of 1.58%. The ex-dividend date was Monday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 83.70%.

Analysts Set New Price Targets

Several brokerages recently weighed in on BDX. Raymond James dropped their target price on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Evercore ISI boosted their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. Stifel Nicolaus boosted their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Finally, StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $282.63.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.